IMMX - NASDAQ
Immix Biopharma, Inc.
$8.63
+3.2%Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
At a Glance
Live Snapshotimmx
Total Liabilities and Equity
Last Annual Value
104.84M
3-Year CAGR
92%
5-Year CAGR
187%
10-Year CAGR
60%
Immix Biopharma, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Immix Biopharma, Inc. NASDAQ:IMMX | 104.84M | 73.9% | 41.9% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 288.97M | -19.9% | -9.3% | N/A | |
 Coya Therapeutics, Inc. NASDAQ:COYA | 49.95M | 6.6% | 59.8% | N/A | |
 CAMP4 Therapeutics Corporation NASDAQ:CAMP | 117.81M | 28.9% | -21.8% | -11.7% | |
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 130.94M | 7.6% | -5.1% | N/A | |
 Clene Inc. NASDAQ:CLNN | 18.13M | -29.8% | -22.1% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 141.31M | -20.2% | -14.3% | N/A | |
 CervoMed Inc. NASDAQ:CRVO | 43.08M | 62.9% | 2.6% | 9.4% | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 154.42M | -1.1% | -6.1% | 4.6% | |
 Gain Therapeutics, Inc. NASDAQ:GANX | 22.82M | 7.0% | -10.2% | N/A | |
 XBiotech Inc. NASDAQ:XBIT | 150.08M | -12.8% | -11.4% | 8.4% |
Immix Biopharma, Inc. Fair Value Envelope
Related Guides
Continue your IMMX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.